Stakeholder Insight - Chronic Leukemias - Is there room left for improvement? - http://www.companiesandmarkets.com adds new report

2008-12-05 14:19:00 - Stakeholder Insight - Chronic Leukemias - Is there room left for improvement? - a new market research report on www.companiesandmarkets.com

www.companiesandmarkets.com/Summary-Market-Report/Stakeholder-In ..

Introduction

CLL is the most common form of leukemia in western countries. Recent therapeutic advances have improved the rate and duration of remission, although there is no consensus over the optimum regimen. CML has a lower incidence than CLL, but is a commercially lucrative indication for Gleevec (imatinib; Novartis) which continues to enjoy blockbuster success, having revolutionized the treatment of CML.

Scope

*Analysis of CLL and CML market based on a survey of 180 chronic leukemia specialists, supported by interviews carried out with key opinion leaders

*Segmentation of CLL and CML population by disease stage at presentation and proportion receiving anti-cancer therapy

*In-depth analysis of treatment patterns, regimens prescribed and treatment outcomes for CLL and CML by line of therapy and disease stage

*Ranking of key prescribing influences in CLL and CML, brand assessment of existing drug therapies, unmet needs and late-phase pipeline overview

Highlights

Rituxan (rituximab; Biogen Idec/Genentech/Roche/Zenyaku Kogyo) has received considerable off-label use for chronic lymphocytic leukemia (CLL), particularly in the US. Positive Phase III data are likely to drive increased uptake in the EU. Conversely, several factors have restricted uptake of Campath (alemtuzumab; Takeda/Genzyme/Bayer Schering).

Gleevec is firmly established as the standard-of-care for newly diagnosed chronic phase CML, while the second generation tyrosine kinase inhibitors Sprycel (dasatinib; Bristol-Myers Squibb) and Tasigna (nilotinib; Novartis) are experiencing increasing uptake in Gleevec-resistant and accelerated phase patients.

Sprycel currently commands a higher market share than Tasigna for CML, benefiting from its first-to-market advantage. However, physicians´ perceptions of Sprycel and Tasigna show little differentiation, and there will be close competition for market share in the coming years.

Reasons to Purchase

*Understand prescribing trends and identify key factors that influence treatment choices in CLL and CML

*Examine unmet need within the CLL and CML markets and identify opportunities for new product development

*Enhance commercial positioning by increasing understanding of current dynamics within the CLL and CML markets